[HTML][HTML] Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study
H Fan, W Wang, Y Zhang, J Wang… - Cancer Biology & …, 2023 - ncbi.nlm.nih.gov
Objective: Evidence on the prognostic value of autologous stem cell transplantation (ASCT)
and minimal residual disease (MRD) dynamics of patients with newly diagnosed multiple …
and minimal residual disease (MRD) dynamics of patients with newly diagnosed multiple …
The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center
Y Yang, J Li, W Wang, Y Wang, A Maihemaiti… - Cancer …, 2023 - Wiley Online Library
Background Significant advances in multiple myeloma (MM) over the past 15 years led to
exciting changes in the management of MM patients in China, which in turn brought about …
exciting changes in the management of MM patients in China, which in turn brought about …
Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom
M Mohty, W Knauf, D Romanus… - European journal of …, 2020 - Wiley Online Library
Objectives The treatment paradigm in newly diagnosed multiple myeloma (NDMM) is
evolving toward individualized, risk‐directed, and longer duration of therapy (DOT). The …
evolving toward individualized, risk‐directed, and longer duration of therapy (DOT). The …
[HTML][HTML] Survival of multiple myeloma patients in the era of novel agents and autologous stem cell transplantation: a multicenter retrospective collaborative study of the …
S Ozaki, H Handa, T Saitoh, H Murakami, M Itagaki… - Blood, 2014 - Elsevier
Introduction A significant progress in the management of multiple myeloma (MM) has been
made in recent years by the introduction of novel treatment modalities including high-dose …
made in recent years by the introduction of novel treatment modalities including high-dose …
[HTML][HTML] Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma
G Ravi, WI Gonsalves - Cancer treatment and research communications, 2021 - Elsevier
Multiple myeloma (MM) is a hematological malignancy characterized by the clonal
proliferation of plasma cells in the bone marrow. It is mostly observed in older adults with a …
proliferation of plasma cells in the bone marrow. It is mostly observed in older adults with a …
[HTML][HTML] Real-world data on clinical features, outcomes, and prognostic factors in multiple myeloma from Miyazaki Prefecture, Japan
K Akizuki, H Matsuoka, T Toyama, A Kamiunten… - Journal of Clinical …, 2020 - mdpi.com
The prognosis of multiple myeloma (MM) has improved with the introduction of novel agents.
These data are largely derived from clinical trials and might not reflect real-world patient …
These data are largely derived from clinical trials and might not reflect real-world patient …
Survival and outcomes of newly diagnosed multiple myeloma patients stratified by transplant status 2007-2018: retrospective analysis from the Canadian Myeloma …
H Mian, D Reece, E Masih-Khan, A McCurdy… - … Myeloma and Leukemia, 2022 - Elsevier
Background Considerable progress has been made in therapeutic options for multiple
myeloma (MM). Understanding the current landscape of MM treatment options and …
myeloma (MM). Understanding the current landscape of MM treatment options and …
Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: A retrospective single-center analysis
M Mair, C Straka, T Buratti, M Tauber, M Mitterer… - Annals of …, 2020 - Springer
High-dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT) as
well as the introduction of novel agents (NA) significantly improved survival for patients with …
well as the introduction of novel agents (NA) significantly improved survival for patients with …
[HTML][HTML] Improvement in survival of multiple myeloma patients: a long-term institutional experience
J Nunnelee, Q Zhao, DM Benson Jr, AE Rosko… - Blood, 2019 - Elsevier
Introduction-Multiple myeloma (MM) represents 1.8% of all new cancer cases in the US, with
an estimated 32,110 new cases in 2019. While not curable, advances in treatment, including …
an estimated 32,110 new cases in 2019. While not curable, advances in treatment, including …
[HTML][HTML] Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7 …
X Han, C Jin, G Zheng, D He, Y Zhao, Y Li… - Frontiers in …, 2021 - frontiersin.org
Introduction We analyzed different patient subgroups to determine optimal maintenance
therapy in newly diagnosed multiple myeloma (NDMM) patients. Methods A total of 226 …
therapy in newly diagnosed multiple myeloma (NDMM) patients. Methods A total of 226 …